Patent Application
20220347186
This disclosure relates to methods for treatment of sickle cell anemia and thalassemia.
Genetic (inherited) blood disorders are blood diseases that are passed from chromosomes of parents to those of their children. Some such diseases are severe and can cause life-long health challenges. Disorders affecting hemoglobin, a protein in red blood cells that carries oxygen throughout the body, can be particularly challenging to address. A deficiency or mutation in hemoglobin often leads to anemia, a condition in which a patient can feel tired, weak, or short of breath. Severe anemia can cause organ damage and death.
Sickle cell disease (SCD) is a group of inherited red blood cell disorders. In patients with SCD, the hemoglobin is mutated and forms into stiff rods within the red blood cells. This changes the shape of the red blood cells that carry the protein: healthy cells are disc-shaped, but SCD-affected hemoglobin causes cells to be a crescent (sickle) shape.
The sickle-shaped cells are not flexible, and many of them burst apart as they move through blood vessels. Sickle cells usually only last 10 to 20 days, instead of the normal 90-120 day lifespan of red blood cells. The patient's body may have trouble making enough new cells to replace the ones that are lost prematurely. The resulting deficiency of red blood cells causes anemia. The sickle-shaped cells can also stick to vessel walls, causing a blockage that slows or stops the flow of blood. When this happens, oxygen cannot reach nearby tissues. The lack of oxygen can cause attacks of sudden, severe pain called pain crises and/or strokes when the brain is deprived of oxygen. These attacks can occur without warning, and patients are often hospitalized for these pain crisis events. Bone marrow transplants offer the only opportunity for cure and are usually reserved for young patients.
Thalassemia is another inherited blood disorder in which the body is unbalanced in its production of the hemoglobin chains. Because of this imbalance, the hemoglobin protein does not form normally, causing red blood cells to not function properly and last for shorter periods of time, leading to anemia. The disorder can cause the bone marrow to expand, leading to bone deformities. Some thalassemia patients require regular blood transfusions.
In light of the continued burden of inherited blood disorders on families, there is a need for new treatments to address inherited blood disorders, such as sickle cell anemia and thalassemia.
This disclosure describes methods and compositions for treating inherited blood disorders, including sickle cell anemia and thalassemia.
As described below, in a first aspect the present disclosure provides a method of treating an inherited blood disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a bromodomain and extra-terminal motif (BET) protein inhibitor.
In one embodiment of the first aspect, the inherited blood disorder is thalassemia. In one embodiment, the thalassemia is alpha thalassemia. In one embodiment, the thalassemia is beta thalassemia.
In one embodiment of the first aspect, the inherited blood disorder is sickle cell anemia. In one embodiment, the sickle cell anemia is type HbSS. In one embodiment, the sickle cell anemia is type HbSC. In one embodiment, the sickle cell anemia is type HbS beta thalassemia. In one embodiment, the sickle cell anemia is type HbSD, HbSE, or HbSO.
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is JQ1.
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is CPI-0610.
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is PLX51107.
In one embodiment of the first aspect or embodiments thereof, the BET protein inhibitor inhibits bromodomain-containing protein 4 (BRD4).
In one embodiment of the first aspect or embodiments thereof, the BET protein inhibitor inhibits bromodomain-containing protein 2 (BRD2), bromodomain-containing protein 3 (BRD3), bromodomain-containing protein 4 (BRD4), and/or bromodomain testis-specific protein (BRDT).
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is administered to the subject orally.
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is administered to the subject intravenously.
In one embodiment of the first aspect or embodiments thereof, the BET inhibitor is administered to the subject in conjunction with a second therapy. In one embodiment, the second therapy comprises a histone deacetylase (HDAC) inhibitor. In one embodiment, the second therapy comprises an antineoplastic agent. In one embodiment, the antineoplastic agent comprises hydroxyurea. In one embodiment, the second therapy comprises an HbS polymerization inhibitor. In one embodiment, the HbS polymerization inhibitor is voxelotor. In one embodiment, the second therapy is a gene therapy approach. In one embodiment, the gene therapy approach comprises a lentiviral vector. In one embodiment, the gene therapy approach comprises gene editing.
In a second aspect, the present disclosure provides a method of inducing expression of fetal and/or embryonic hemoglobin in a subject, comprising administering a bromodomain and extra-terminal motif (BET) protein inhibitor to the subject.
In one embodiment of the second aspect, the fetal hemoglobin is hemoglobin F (HbF).
In one embodiment of the second aspect, the fetal hemoglobin is embryonic hemoglobin (HbE).
In one embodiment of the second aspect, the BET inhibitor is JQ1.
In one embodiment of the second aspect or embodiments thereof the BET inhibitor is CPI-0610.
In one embodiment of the second aspect or embodiments thereof, the BET inhibitor is PLX51107.
In one embodiment of the second aspect or embodiments thereof, the BET protein inhibitor inhibits bromodomain-containing protein 4 (BRD4).
In one embodiment of the second aspect or embodiments thereof, the BET protein inhibitor inhibits bromodomain-containing protein 2 (BRD2), bromodomain-containing protein 3 (BRD3), bromodomain-containing protein 4 (BRD4), and bromodomain testis-specific protein (BRDT).
In one embodiment of the second aspect or embodiments thereof, the BET inhibitor is administered to the subject orally.
In one embodiment of the second aspect or embodiments thereof, the BET inhibitor is administered to the subject intravenously.
In one embodiment of the first aspect, the therapeutically effective amount of the BET protein inhibitor induces expression of fetal and/or embryonic hemoglobin in the subject. In one embodiment, the expressed fetal and/or embryonic hemoglobin alleviates one or more symptoms of an inherited blood disorder in the subject. In one embodiment, the one or more symptoms of the inherited blood disorder comprises reduced clotting, excessive bleeding, fatigue, dizziness, malaise, anemia, joint pain, chest pain, delayed development, jaundice, or dactylitis.
In a third aspect, the present disclosure provides a method of inducing erythropoiesis in a subject, comprising administering to the subject a therapeutically effective amount of a bromodomain and extra-terminal motif (BET) protein inhibitor to the subject.
In one embodiment of the first, second, or third aspect, the BET inhibitor is one or more of JQ1, I-BET 151, I-BET 762, OTX-015, TEN-010, CPI-203, CPI-0610, olinone, RVX-208, LY294002, AZD5153, MT-1, MS645, RVX-297, PLX51107, BMS-986158, FT-1101, INCB054329, INCB057643, and ZEN-3694.
These and other features and advantages of the present invention will be more fully understood from the following detailed description taken together with the accompanying claims. It is noted that the scope of the claims is defined by the recitations therein and not by the specific discussion of features and advantages set forth in the present description.
The accompanying drawings are included to provide a further understanding of the methods and compositions of the disclosure, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s) of the disclosure, and together with the description serve to explain the principles and operation of the disclosure. For all figures, *p<0.05, **p<0.01, ***p<0.001.
Provided herein are methods and compositions for treatment of sickle cell anemia and thalassemia.
It is to be understood that the particular aspects of the specification are described herein are not limited to specific embodiments presented, and can vary. It also will be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting. Moreover, particular embodiments disclosed herein can be combined with other embodiments disclosed herein, as would be recognized by a skilled person, without limitation.
Throughout this specification, unless the context specifically indicates otherwise, the terms “comprise” and “include” and variations thereof (e.g., “comprises,” “comprising,” “includes,” and “including”) will be understood to indicate the inclusion of a stated component, feature, element, or step or group of components, features, elements or steps but not the exclusion of any other component, feature, element, or step or group of components, features, elements, or steps. Any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms, while retaining their ordinary meanings.
As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise.
Percentages disclosed herein can vary in amount by ±10, 20, or 30% from values disclosed and remain within the scope of the contemplated disclosure.
Unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values herein that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. For example, “about 5%” means “about 5%” and also “5%.” The term“about” can also refer to ±10% of a given value or range of values. Therefore, about 5% also means 4.5%-5.5%, for example.
As used herein, the terms “or” and “and/or” are utilized to describe multiple components in combination or exclusive of one another. For example, “x, y, and/or z” can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.”
“Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio or which have otherwise been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
“Therapeutically effective amount” or “effective amount” refers to that amount of a therapeutic agent, such as a BET inhibitor, which when administered to a subject, is sufficient to effect treatment (e.g., improve symptoms) for a disease or disorder described herein, such as sickle cell disease. The amount of a compound which constitutes a “therapeutically effective amount” or “effective amount” can vary depending on the compound, the disorder and its severity, and the age, weight, sex, and genetic background of the subject to be treated, but can be determined by one of ordinary skill in the art.
“Treating” or “treatment” as used herein refers to the treatment of a disease or disorder described herein, in a subject, preferably a human, and includes inhibiting, relieving, ameliorating, or slowing progression of the disease or disorder or one or more symptoms of the disease or disorder.
“Subject” refers to a warn blooded animal such as a mammal, preferably a human, which is afflicted with, or has the potential to be afflicted with one or more diseases and disorders described herein.
“Pharmaceutical composition” as used herein refers to a composition that includes one or more therapeutic agents disclosed herein, such as a BET protein inhibitor, a pharmaceutically acceptable carrier, a solvent, an adjuvant, and/or a diluent, or any combination thereof.
In view of the present disclosure, the methods and compositions described herein can be configured by the person of ordinary skill in the art to meet the desired need. In general, the disclosed materials and methods provide improvements in treating sickle cell anemia and thalassemia and similar blood disorders.
Inherited blood disorders manifest with a variety of symptoms. Some affect clotting (by reducing or effectively eliminated clotting) leading to easy bruising and/or excessive bleeding (e.g., frequent nosebleeds or excessive bleeding during or after invasive procedures). Hemophilia and von Willebrand Disease are examples of these clotting disorders. Other disorders affect the production or maintenance of red blood cells, and a number of these disorders affect hemoglobin. Additional symptoms associated with inherited blood disorders include fatigue, dizziness, malaise, anemia, joint pain, chest pain, delayed development, jaundice, and dactylitis.
Hemoglobin is an iron-rich protein in red blood cells. Oxygen entering the lungs attaches to the hemoglobin in the blood, which carries it to the tissues in the body. The oxygen is released from the hemoglobin in tissues throughout the body, allowing for aerobic respiration. When a subject has insufficient red blood cells or red blood cells that do not work properly, the body is left short of the oxygen it needs to function.
Human hemoglobin is a tetramer consists of two α-like globins and two β-like globins. The β-like globins are encoded by a cluster of genes located on chromosome 11p15.4 (HBB cluster). The HBB cluster consists of five genes: 5′-HBE1-HBG2-HBG1-HBD-HBB-3′. These genes are expressed during different stages of human development and undergo a series of epigenetic switches. HBE1 is expressed in the early embryonic stage and makes up the embryonic hemoglobins (Hb-Gower 1, ζ2ε2, and Hb-Gower 2, α2ε2) (1-3). HBG1 and HBG2 expression surpass HBE1 in the early fetal stage to make fetal hemoglobin (HbF, α2γ2), which is the predominant form of hemoglobin until months after birth. The switch from fetal to adult hemoglobin (HbA, α2β2) starts soon after birth, where HBB expression overtakes HBG1/2 to become the predominant form of hemoglobin (1,4). This switch does not completely shut down HbF production, and normal adults have HbF consisting ˜1% of all hemoglobin.
Expression of β-globin locus genes is under the control of locus control region (LCR), an enhancer-rich region 5′ of the gene cluster. Previous studies have shown that transcription factors (TFs) binding LCR promote looping and bring the enhancers in contact with promoters of β-globin genes (2). Forced looping of LCR to HBG1 and HBG2 leads to reactivation of HbF in adult CD34+ hematopoietic stem cells (HSCs) during erythropoiesis (5,6). In particular, the erythroid-lineage TFs GATA1 and KLF1 promote looping of LCR to the promoter of HBB (7-9). Notably, GATA1 requires the assistance of BET bromodomain proteins (e.g., BRD2, BRD3, BRD4, and BRDT) to bind to the β-globin locus (10,11).
The bromodomain (BRD) is a 110 amino acid protein domain that can recognize monoacetylated lysine residues. The recognition is a prerequisite for chromatin remodelling, and BRD-containing proteins play an important role in directing chromatin remodelling enzymes to specific sites. The BET family of proteins is characterized by the presence of two tandem bromodomains plus an extra-terminal (ET) domain. The ET domain is a conserved region of ˜80 amino acids that performs a regulatory function by recruiting specific effector proteins. The mammalian BET family of proteins comprises bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) and bromodomain testis-specific protein (BRDT).
BET bromodomain inhibitors can cause reversion of the fetal-adult hemoglobin switch and increase the proportion of HbF in adult erythrocytes. Sickle cell anemia and thalassemia are genetic disorders that affect hemoglobin. There is a variety of subtypes of sickle cell anemia (also known as sickle cell disease, or SCD) with different genetic components. In the HbSS subtype, the subject inherits two sickle cell genes (“S”), one from each parent. This subtype is usually the most severe form of the disease. Subjects with HbSC inherit a sickle cell gene (“S”) from one parent and a gene for an abnormal hemoglobin called “C” from the other parent. This subtype is usually a milder form of SCD. Subjects who have HbS beta thalassemia inherit one sickle cell gene (“S”) from one parent and one gene for beta thalassemia from the other parent. There are two types of beta thalassemia: “0” and “+”. Those with HbS beta 0-thalassemia usually have a severe form of SCD. People with HbS beta +-thalassemia tend to have a milder form of SCD. There also are a few rarer types of SCD: HbSD, HbSE, and HbSO. People who have these forms of SCD inherit one sickle cell gene (“S”) and one gene for an abnormal type of hemoglobin (“D”, “E”, or “O”). The severity of these rarer types of SCD varies.
In individuals who have sickle cell trait (SCT), or HbAS, one sickle cell gene (“S”) is inherited from one parent and one normal gene (“A”) from the other parent. People with SCT usually do not have any of the signs of the disease and live a normal life, but they can pass the trait on to their children. Additionally, there are a few uncommon health problems that may be related to sickle cell trait.
Thalassemia has two main types: alpha thalassemia and beta thalassemia. In alpha thalassemia, the hemoglobin does not contain enough alpha protein. To make alpha-globin protein chains, four genes are needed: two on each chromosome 16. If one or more of these genes is missing, alpha thalassemia will result. Two globin genes are needed to make beta-globin chains—one on each chromosome 11. If one or both genes are faulty, beta thalassemia will occur. The severity of thalassemia in each case depends on how many genes are faulty, or mutated. The words “trait,” “minor,” “intermedia,” or “major” are used to describe the severity of thalassemia. For example, a person who has thalassemia trait may not have any symptoms at all or may have only mild anemia, while a person with thalassemia major may have severe symptoms and may need regular blood transfusions.
Based on the present disclosure, it is believed that inhibitors of bromodomain and extra-terminal motif (BET) proteins (referred to as “BET protein inhibitors” or “BET inhibitors”) can be effective for treating different subtypes of sickle cell disease and various types and severities of thalassemia. While not wishing to be bound by theory, it is believed that BET protein inhibitors can be used to induce and/or enhance the expression of normal fetal and/or embryonic hemoglobin genes in individuals having mutated adult hemoglobin genes to alleviate symptoms of different subtypes of sickle cell disease and/or various types and severities of thalassemia.
Inhibitors of BET proteins prevent the protein-protein interactions between BET proteins and acetylated histones and transcription factors. A BET inhibitor can modulate activity of one or more of BRD2, BRD3, BRD4, and BRDT. Non-limiting examples of BET inhibitors contemplated for use in the present disclosure include one or more of JQ1 (a thienotriazolodiazepine; available from Sigma-Aldrich), I-BET 151 (GlaxoSmithKline), I-BET 762 (also known as GSK525762, molibresib; GlaxoSmithKline), OTX-015 (also known as MK-8628; Merck Sharp & Dohme Corporation), TEN-010 also known as RO6870810 (Hoffman La-Roche), CPI-203 (Constellation Pharmaceuticals), CPI-0610 (Constellation Pharmaceuticals), olinone, RVX-208 (also known as RVX000222, apabetalone; Resverlogix Corporation), LY294002, AZD5153 (AstraZeneca), MT-1, MS645, and RVX-297 (Resverlogix Corporation), PLX51107 (Plexxicon), BMS-986158 (Bristol-Myers Squibb), FT-1101 (Forma Therapeutics), INCB054329 (InCyte Corporation), INCB057643 (InCyte Corporation), ZEN-3694 (Zenith Epigenetics), and combinations thereof.
Compositions
In some embodiments, pharmaceutical compositions contemplated herein include a therapeutically effective amount of one or more BET inhibitors. Such compositions may further include an appropriate pharmaceutically acceptable carrier, solvent, adjuvant, diluent, or any combination thereof. The exact nature of the carrier, solvent, adjuvant, or diluent will depend upon the desired use (e.g., route of administration) for the composition, and may range from being suitable or acceptable for veterinary uses to being suitable or acceptable for human use.
BET inhibitors of the present disclosure can be administered through a variety of routes and in various compositions. For example, compositions containing BET inhibitors can be formulated for oral, intravenous, topical, ocular, buccal, systemic, nasal, injection, transdermal, rectal, or vaginal administration, or formulated in a form suitable for administration by inhalation or insufflation. In some embodiments of the present disclosure, administration is oral or intravenous.
A variety of dosage schedules is contemplated by the present disclosure. For example, a subject can be dosed monthly, every other week, weekly, daily, or multiple times per day. Dosage amounts and dosing frequency can vary based on the dosage form and/or route of administration, and the age, weight, sex, and/or severity of the subject's disease. In some embodiments of the present disclosure, one or more BET inhibitors is administered orally, and the subject is dosed on a daily basis.
The therapeutic agents (also referred to as “compounds” herein) described herein (e.g., BET inhibitors and secondary therapeutic agents), or compositions thereof, will generally be used in an amount effective to achieve the intended result, for example, in an amount effective to provide a therapeutic benefit to subject having the particular disease being treated. As used herein, therapeutic benefit refers to the eradication or amelioration of the underlying disease being treated and/or eradication or amelioration of one or more of the symptoms associated with the underlying disease such that a subject being treated with the therapeutic agent reports an improvement in feeling or condition, notwithstanding that the subject may still be afflicted with the underlying disease.
Non-limiting examples of contemplated secondary therapeutic agents include one or more histone deacetylase (HDAC) inhibitors. Examples of histone deacetylase inhibitors include panobinostat, entinostat, romidepsin, and vorinostat. Other therapies can comprise an antineoplastic agent. In some embodiments, the antineoplastic agent is hydroxyurea. Other therapies can also include an HbS polymerization inhibitor. In some embodiments, the HbS polymerization inhibitor is voxelotor. Other therapies can include administration of a hematopoietic stem cell mobilizer. The stem cell mobilizer can be plerixafor.
Determination of an effective dosage of compound(s) for a particular disease and/or mode of administration is well known. Effective dosages can be estimated initially from in vitro activity and metabolism assays. For example, an initial dosage of compound for use in a subject can be formulated to achieve a circulating blood or serum concentration of the metabolite active compound that is at or above an IC50 of the particular compound as measured in an in vitro assay. Calculating dosages to achieve such circulating blood or serum concentrations taking into account the bioavailability of the particular compound via a given route of administration is well within the capabilities of a skilled artisan. Initial dosages of compound can also be estimated from in vivo data, such as from an appropriate animal model.
Dosage amounts of BET inhibitors and secondary therapeutic agents can be in the range of from about 0.0001 mg/kg/day, about 0.001 mg/kg/day, or about 0.01 mg/kg/day to about 100 mg/kg/day, but may be higher or lower, depending upon, among other factors, the activity of the active compound, the bioavailability of the compound, its metabolism kinetics and other pharmacokinetic properties, the mode of administration and various other factors, including particular condition being treated, the severity of existing or anticipated physiological dysfunction, the genetic profile, age, health, sex, diet, and/or weight of the subject. Dosage amounts and dosing intervals can be adjusted individually to maintain a desired therapeutic effect over time. For example, the compounds may be administered once, or once per week, several times per week (e.g., every other day), once per day or multiple times per day, depending upon, among other things, the mode of administration, the specific indication being treated and the judgment of the prescribing physician. In cases of local administration or selective uptake, such as local topical administration, the effective local concentration of compound(s) and/or active metabolite compound(s) may not be related to plasma concentration. Skilled artisans will be able to optimize effective dosages without undue experimentation.
For example, a dosage contemplated herein can include a single volume of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, or 3.0 ml of a pharmaceutical composition having a concentration of a BET inhibitor at about 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 10, 15, 20, 50, 100, 200, 500, or 1000 μM in a pharmaceutically acceptable carrier.
In some embodiments, the subject is tested before treatment to determine which BET inhibitor will be most effective. This testing can be performed by isolating primary hematopoietic stem cells from the subject and performing an in vitro drug screening. The BET inhibitor found to be most effective in the isolated hematopoietic stem cells of the subject, for example, resulting in the most desirable gene expression in the cells, can be used to treat the subject.
Methods
In some embodiments, methods of treating an inherited blood disorder in a subject in need thereof include administering to the subject a therapeutically effective amount of one or more bromodomain and extra-terminal motif (BET) protein inhibitors and optionally a second therapy and/or secondary therapeutic agent. Treatable inherited blood disorders can include thalassemias (alpha thalassemia and beta thalassemia) and sickle cell anemia (type HbSS, HbSC, HbS beta thalassemia, HbSD, HbSE, or HbSO.
In some embodiments, the therapeutic methods contemplated herein include inhibiting bromodomain-containing protein 4 (BRD4), bromodomain-containing protein 2 (BRD2), bromodomain-containing protein 3 (BRD3), bromodomain-containing protein 4 (BRD4), and/or bromodomain testis-specific protein (BRDT).
In some embodiments, the therapeutic methods contemplated herein include administering to the subject a pharmaceutical composition to the subject orally and/or intravenously.
In some embodiments, the therapeutic methods contemplated herein include administering to the subject a pharmaceutical composition including both one or more BET protein inhibitors and one or more secondary therapeutic agents. In other embodiments, the therapeutic methods include administering a first pharmaceutical composition including one or more BET protein inhibitors and a second pharmaceutical composition including one or more secondary therapeutic agents.
In some embodiments, the therapeutic methods contemplated herein include administering to the subject a pharmaceutical composition including one or more BET protein inhibitors and administering a gene therapy approach to treat the inherited blood disorder in the subject. For example, the gene therapy approach can be administration of a lentiviral vector to the subject and/or ex vivo gene editing of hematopoietic tissues taken from the subject.
In some embodiments, the therapeutic methods contemplated herein include inducing expression of fetal and/or embryonic hemoglobin in a subject by administering a bromodomain and extra-terminal motif (BET) protein inhibitor to the subject. For example, the hemoglobin can be fetal hemoglobin F (HbF) and/or embryonic hemoglobin (HbE) and the expressed fetal and/or embryonic hemoglobin can alleviate one or more symptoms of an inherited blood disorder in the subject. In some embodiments, the one or more symptoms of the inherited blood disorder comprises reduced clotting, excessive bleeding, fatigue, dizziness, malaise, anemia, joint pain, chest pain, delayed development, jaundice, or dactylitis.
In some embodiments, the therapeutic methods contemplated herein include a method of inducing erythropoiesis in a subject including administering to the subject a therapeutically effective amount of a bromodomain and extra-terminal motif (BET) protein inhibitor.
In some embodiments, the therapeutic methods contemplated herein include treating a subject having or suspected of having a hemoglobin-related disorder, such as sickle cell anemia, thalassemia, and similar blood disorders, with a therapeutic amount of one or more BET inhibitors including JQ1, I-BET 151, I-BET 762, OTX-015, TEN-010, CPI-203, CPI-0610, olinone, RVX-208, LY294002, AZD5153, MT-1, MS645, RVX-297, PLX51107, BMS-986158, FT-1101, INCB054329, INCB057643, and ZEN-3694.
In some embodiments, a therapeutic method contemplated herein includes treating a subject having an abnormal hemoglobin by obtaining a sample from the subject (e.g., blood, plasma, urine, saliva, or tissue), detecting an abnormal hemoglobin in the sample, and administering a therapeutic amount of one or more BET inhibitors and/or a secondary therapeutic agent to the subject. In this context, the term “abnormal hemoglobin” refers to any abnormality detected in the subject's hemoglobin such as those that adversely affect hemoglobin structure or hemoglobin function, abnormal hemoglobin expression levels, abnormal hemoglobin clearance rates, abnormal types of hemoglobin expressed, and the like.
In some embodiments of the present disclosure, the response of a subject to BET inhibitor administration is used to diagnose an HBB-related disorder. For example, a method of treating a subject for an HBB-related disorder can include administering a therapeutically effective amount of a BET inhibitor to a subject suspected of having HBB-related disorder, and alleviating one or more symptoms associated with the HBB-related disorder, wherein the alleviation of the one or more symptoms by administration of the BET inhibitor is indicative of the subject having an inherited blood disorder.
In some embodiments, one or more BET inhibitors can be administered in conjunction with another therapy or therapies for an inherited blood disorder (a second therapy or secondary therapeutic agent). In some embodiments, the BET inhibitor is delivered concurrently with the other therapy or therapies or administration can be in series (e.g., a BET inhibitor is administered before or after a secondary therapeutic agent).
In some embodiments, the BET inhibitor treatment is accompanied by a gene therapy approach. The gene therapy can be performed ex vivo, and the subject can be treated with autologous hematopoietic cells. The gene therapy approaches can function, for example, by adding a cassette to drive expression of a normal beta chain. The gene therapy approach can comprise a lentiviral therapy. The lentiviral vector can comprise, for example, a human β-A-T87Q globin gene (LentiGlobin BB305, bluebird bio).
Alternatively or in addition, the gene therapy approach can function through gene editing. For example, the gene therapy approach can use clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated protein 9 (Cas9), zinc finger nuclease, or related technologies to correct one or more defective genes, or alter expression of compensatory genes. For example, the gene therapy approach can involve engineering hematopoietic stem cells to produce high levels of fetal hemoglobin by editing the BCL11A gene (CTX001, Vertex/CRISPR Therapeutics; BIVV003, Bioverativ/Sangamo).
The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only and should not be construed as limiting the scope of the disclosure in any way.
The human hemoglobin genes consist of three distinct types of hemoglobin expressed at different developmental stages. The embryonic hemoglobin is produced at the earliest stages of embryonic development and is soon replaced by fetal hemoglobin (HbF). HbF persists throughout prenatal development and is overtaken by the production of adult hemoglobin (HbA) after a few months after birth. The mechanisms resulting in the fetal to adult hemoglobin switch at the β-globin locus involves numerous protein complexes and relies on proper chromatin looping. In inherited blood disorders that involve mutations in the adult hemoglobin gene, such as sickle cell anemia (SCA), a major treatment strategy is to reactivate fetal hemoglobin to partially replace the mutated sickle hemoglobin (HbS). However, options for pharmacological inducers of fetal hemoglobin remain few beyond hydroxyurea. Here, it is reported that BET inhibitors induced specific upregulation of fetal and embryonic hemoglobin production in vitro. In cells expressing the adult hemoglobin gene HBB, JQ1 treatment reduces the proportion of adult hemoglobin transcripts in favor of fetal and embryonic hemoglobin genes. Mechanistically, JQ1 treatment reduces the expression of fetal hemoglobin inhibitors MYB and BCL11A. In TF-1 cells, JQ1 also upregulates the lncRNA gene BGLT3, which leads to increased enhancer contact with the HbF genes. These results suggest that small molecule BET inhibitors could have clinical utility in the treatment of SCA and other inherited hemoglobinopathies by upregulating HbF and embryonic hemoglobin genes.
Previous studies have shown that BET inhibitors induce differentiation of erythroid cell lines UT7, but they did not characterize which hemoglobin genes were expressed (12). Although some studies have performed RNA-seq on JQ1-treated K562 cells, none has focused on the differentiation properties of JQ1, and the length of the treatment was generally too short to characterize erythropoietic phenotypes (13-16). Here, how BET inhibitors affect the interaction between the LCR and its target hemoglobin genes and the expression of genes regulating erythropoiesis was examined. It was hypothesized that BET inhibitors would promote expression of erythropoietic genes and suppress genes involved in myeloid differentiation. In addition, since BET proteins are heavily involved in the looping between LCR and the adult hemoglobin genes, it was reasoned that BET bromodomain inhibitors would disrupt this interaction and increase the expression of fetal and embryonic hemoglobins, suggesting likely clinical utility.
Cell Lines and BET Inhibitor Treatments
K562, HEL, and HL-60 cells were cultured in RPMI 1640 medium supplemented with 10% FBS. TF-1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 4 ng/mL GM-CSF. Before treatment, TF-1 cells were washed 4× with RPMI 1640 without supplements, and cultured in RPMI 1640 medium with 10% FBS but no GM-CSF for 24 hours. 4 ng/mL GM-CSF or 3 units/mL EPO were added at the time of treatment set up. K562, HEL, and HL-60 cells were cultured as normal until treatment set up. JQ1 (Sigma-Aldrich, SML1524), CPI-0610 (Selleck Chemicals, S7853), and PLX51107 (MedChemExpress, HY-111422) were dissolved in DMSO to 10 mM concentration and stored in −80° C. All three inhibitors were applied to cells at 200 nM, with parallel DMSO treatment (0.002%) as control. JQ1 and PLX51107 were added to cell culture at day 0 without additional treatments up to day 5. CPI-0610 was reapplied to the cells on a daily basis.
Cytospin and Benzidine-Hematoxylin Staining
K562 cells were counted, and 200,000 cells were collected by spinning at 400 g. Culture media was discarded, and cells were re-suspended in 100 μL of PBS. The cells were spun onto glass slides at 600 rpm, which were allowed to dry for ˜20 minutes before staining. The slides were stained in 0.2% benzidine solution in 0.5 M acetic acid for 4 minutes, followed by 2 minutes in 2% H2O2 in 70% ethanol, and 3 minutes washing in running tap water. After the wash, the slides were further stained in 1× hematoxylin solution for 1 minute, followed by another 3 minutes wash in running tap water. The slides were then air-dried and mounted.
Microscopy and Quantification of Benzidine Staining
At least three randomly selected fields of stained cells were imaged at 40× magnification. Images were processed using the Color Deconvolution plugin in ImageJ software to separate hematoxylin and benzidine staining to different channels (37). The numbers of benzidine-positive cells and the intensity of benzidine staining were quantified in the benzidine channel, whereas the total cell number and abnormal nuclear morphology were quantified in the hematoxylin channel. Results of all fields from each slide were summed for the final quantification.
qPCR Quantification of Gene Expression
cDNA libraries for mRNAs were made from 1 μg input RNA using High-Capacity cDNA Reverse Transcription Kit (ThermoFisher, 4368814). Gene expressions were quantified using Power SYBR Green PCR Master Mix (Thermofisher, 4367659). Primer sequences used in qPCR are listed in Table 1. For microRNAs, cDNA libraries were made with Taqman Advanced miRNA cDNA Synthesis Kit (Thermofisher, A28007). miR-15A and miR-16-1 were quantified using the Taqman Advanced miRNA Assays (ThermoFisher, A25576) specific to hsa-miR-15a-5p (assay ID: 477858_mir) and hsa-miR-16-5p (assay ID: 477860_mir).
RNA-seq and Data Processing
Sample RNA libraries were prepared using the KAPA mRNA HyperPrep Kit (Roche, KK8580) with 1 μg input RNA and submitted for sequencing. Raw reads in fastq format were aligned to the hg19 reference genome using HISAT2(38) with Gencode gene and transcript annotation (GRCh37.p13)(39). Gene expression was quantified and compared by tools in the Cuffliks package (40). GO analysis and term clustering was performed using g:Profiler and Cytoscape following the protocols published by Reimand et al (41).
3C-qPCR Quantification of LCR Interaction Frequency
Methods for chromatin conformation capture (3C) qPCR was adapted from Hagège et al. (42). Briefly, 10 million cells were collected and fixed with 1% formaldehyde for 5 minutes in PBS with 10% FBS for 5 minutes, then quenched by 124 mM glycine on ice. The fixed cells were then lysed and digested by 400 units of EcoRI (NEB, R3101). Small aliquots of the samples were taken before and after the digestion as digestion controls. Following the digestion, the samples were diluted and ligated by T4 DNA ligase (NEB, M0202). The samples were then reverse-crosslinked, and DNA was purified by phenol-chloroform extraction. The digestion efficiency, sample purity, and DNA concentration of each sample were assessed by qPCR to exclude low-quality samples prior to the 3C quantification. Previously published 3C primers were used (43,44), listed in Table 1. Primer pairings for all processes in 3C-qPCR are listed in Table 2. Calculated quantity of each primer pairs was normalized as number of templates per million B13 control site template. Additionally, because the Gg primer anneals to both HBG1 and HBG2 fragments, while the Ag primer anneals to only HBG2 fragment, the Gg primer signal was subtracted by Ag primer signal to quantify the HBG1 interaction frequency. All 3C-qPCR was performed using Power SYBR Green PCR Master Mix (ThermoFisher, 4367659).
Immunoprecipitation (IP) and Quantification of Acetyl-GATA1
Nuclear protein was extracted according to previously described protocol (45). 10% of the nuclear protein extraction was saved as input. The remaining nuclear extract was diluted with non-denaturing IP buffer (20 mM Tris-HCl pH 8, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA) and pre-cleared with normal rat IgG (Santa Cruz, sc2026) and Dynabeads Protein G (ThermoFisher, 10004D). Pre-cleared solutions were split into two equal portions, and 5 μg of anti-GATA1 antibody (Santa Cruz, sc266) or normal rat IgG were added to either portion and incubated overnight at 4° C. overnight. Antibodies were then pulled-down using Dynabeads Protein G, and washed 1× with the IP buffer and 2× with PBS containing 1% Triton X-100. The beads were boiled in 2× protein loading buffer to dissociate the proteins. Input and IP-ed proteins were ran on SDS-PAGE gels and transferred to PVDF membranes. The input samples were blotted using anti-topoisomerase 1 (Abcam, ab109374) and anti-GATA1 antibodies, and the IP-ed samples were blotted with anti-acetyl-lysine antibody (Abcam, ab21623). Quantification of signal intensity was done by ImageJ, and GATA1 and acetyl-GATA1 signals were normalized to the topoisomerase 1 signals in each sample.
BET Inhibitor JQ1 Upregulates Fetal and Embryonic Hemoglobin in K562 Cells
BET inhibitors are known to suppress MYC expression. To test whether MYC inhibition leads to enhanced erythroid gene expression, erythroleukemia cell lines were treated with 200 nM JQ1 or DMSO control and incubated for up to 5 days. JQ1 treatment caused K562 and HEL cells to grow slower, but cell viability was unaffected in either cell line (
Quantitative real-time PCR (qPCR) showed that MYC expression was consistently suppressed up to 4 days after the initial treatment (
To define the transcriptomic changes that accompany erythropoiesis, RNA-sequencing (RNA-seq) was performed throughout erythroid differentiation. Although DMSO alone did not induce changes in gene expression (
BET Inhibitors Induce Fetal and Embryonic, but not Adult Hemoglobin
To characterize the types of hemoglobin genes upregulated by JQ1, RT-qPCR primers were designed to quantify the expression of HBB, HBG1/2, and HBE1 in a 5-day time course. Only HBG1/2 and HBE1 were upregulated by JQ1, whereas HBB expression was surprisingly unaffected (
Next, it was determined whether HBG1 and HBG2 were differentially upregulated in K562 and HEL cells. Because the HBG1/2 primers could not distinguish between the two fetal hemoglobin genes, a segment of the HBG1/2 cDNA containing 3 differential bases was amplified and Sanger sequencing was used to measure the difference in signal intensity at each of these base (
RNA-seq data were next examined for both the K562 and TF-1 cells to validate the qPCR results (
Other BET Inhibitors Showed Similar Effects in Erythroleukemia Cell Lines
To ensure that the upregulation of fetal/embryonic hemoglobin observed is not unique to JQ1, two additional BET inhibitors, CPI-0610 and PLX51107, were tested. Unlike JQ1, which has a higher affinity for BRD3 and BRD4 (17), CPI-0610 binds to BRD3, BRD3, BRD4, and BRDT with comparable affinity with a preference for the second bromodomain (BD2) of the BET proteins (18). In contrast, PLX51107 preferentially binds to BD1 and has a somewhat lower affinity for BRDT. CPI-0610 is currently in phase II clinical trials for those with myelofibrosis or myelodysplastic syndrome (MDS) in combination with ruxolitinib. PLX51107 is currently in phase I clinical trials for individuals with acute myeloid leukemia or MDS in combination with azacitidine. Erythroid cell lines were treated with these drugs to measure their effects on the expression of adult, fetal, or embryonic hemoglobin genes. CPI-0610 has a short lifespan in culture medium, and was reapplied daily, whereas PLX51107 was added once at day 0 without additional treatment. Both CPI-0610 and PLX51107 were observed to mimic the effects of JQ1 in K562 and TF-1 cells (
JQ1 Downregulates Known Inhibitors of Fetal Hemoglobin
To understand the mechanisms by which BET inhibitors upregulate fetal and embryonic hemoglobin genes, the expression of known fetal hemoglobin inhibitor genes was examined via RT-qPCR. MYB is an inhibitor of fetal hemoglobin, and is downregulated by the microRNAs miR-ISA and miR-16-1 (3, 20-23). In both K562 and TF-1, MYB expression was significantly suppressed by JQ1 as well as by EPO (
These results were validated with RNA-seq and additioned genes involved in fetal hemoglobin suppression were examined (
JQ1 Modulates Chromatin Spatial Organization at β-Globin Locus
Previous studies showed that expression of different β-globin genes is dependent on the contact frequency between the promoter of each gene and the LCR enhancers (5, 6). Here, chromatin conformation capture (3C) was performed to examine how the spatial structure of this locus changes in response to 72 hours of JQ1 treatment. In K562 cells, JQ1 led to over 2-fold increase in interaction frequency between the LCR and the HBG promoter region, while causing slight increases all throughout the rest of the locus (
A recent study showed that the BGLT3 lncRNA promotes looping between fetal hemoglobin genes and the LCR (26). Therefore, the interaction between the 5′BGLT3 (5′BG) fragment and its upstream loci was examined. In K562 cells, JQ1 significantly increase the interaction frequency of 5′BG with the HBG1/2 region, as well as with the LCR (
GATA1 Protein Level and Acetylation is not Affected by JQ1
To test whether HEMGN downregulation led to decreased acetylation of GATA1, immunoprecipitation (IP) was performed on nuclear protein lysates from JQ1 treated cells along with controls. In K562 cells, JQ1 treatment did not affect the total GATA1 level (
Hemoglobin switch in human development is a well-studied topic and have immense clinical implications. Within the β-globin locus, five hemoglobin genes are expressed under the control of LCR enhancers. Various studies have established that the LCR looping and physical proximity to each hemoglobin gene determine the expression level of these genes (1,2). In fact, forced contact between LCR and the fetal hemoglobins was shown to reactivate fetal hemoglobin expression in adult mice erythroblast (5,6). The 3D structure of the β-globin locus is maintained by many different factors. GATA1 plays a role in maintaining the overall 3D structure of the β-globin locus (8), and is the key transcription factor that promotes LCR binding to adult hemoglobin genes (7). Recent studies have shown that GATA1 binding to erythroid target genes is dependent on its acetylation and association with BET proteins (10,11,29). This raises the possibility of altering the 3D structure β-globin locus by targeting BET proteins. Indeed, previous study has demonstrated that the BET inhibitor JQ1 can promote erythropoiesis in vitro (12), suggesting that BET inhibitors are promising drugs in treating various blood disorders that involve anemia.
In this study, it was discovered that BET inhibitors specifically upregulate fetal and embryonic hemoglobin genes, but had no effect on or even suppressed adult hemoglobin in multiple erythroid cell lines. The findings here has great implications in treating inherited blood disorders involving mutations of the adult hemoglobin genes, notably sickle cell anemia (SCA) and β-thalassemia. SCA is the most common inherited disorder in the United States, and is especially prevalent in many parts of Africa where malaria is common. The most common treatment for SCA is hydroxyurea, which elevates fetal hemoglobin production to alleviate the symptoms. In late 2019, two additional drugs were FDA-approved to treat SCA, voxelotor and crizanlizumab. Voxelotor enhances the affinity of hemoglobin to oxygen, reducing the risk of sickle hemoglobin polymerization in low-oxygen parts of the body (30). Crizanlizumab is an monoclonal antibody against P-selectin, which plays a major part in initiating vaso-occlusive crisis, a common clinical manifestation of SCA (30). Both of these drugs tackle the symptoms caused by sickle cell hemoglobin without reducing the mutant hemoglobin. Although the recent advances in gene therapies made it possible to cure SCA, the high costs for such procedures make them unaffordable for may low-income families. The current findings suggest that the various BET inhibitors, many of which already in clinical trial for blood related disorders, may be suitable addition to the options in treating SCA and other disorders caused by mutations of the HBB gene.
In TF-1 cells, it was found that JQ1 only upregulates the embryonic hemoglobin gene HBE1. One important question with clinical implication is whether the HBE1 encoded ε-globin can be a reasonable substitute for normal β-globin. Biochemical analysis on the semi-embryonic hemoglobin Hb-Gower 2 (α2ε2) showed that this its P50 for oxygen, affinity to 2,3-BPG, Bohr Coefficient, and Hill Coefficient are comparable to those of HbA (α2β2)(31). Hb-Gower 2 also has a comparable tetramer-dimer disassociation constant to that of HbA (32). A study in transgenic α/β-thalassemia mice found that human embryonic hemoglobins HBZ1 (ζ-globin) and HBE1 (ε-globin) rescue the lethal phenotype of α/β-thalassemia (33). Similarly, a study in sickle cell mice found that the presence of human Hb-Gower 2 greatly alleviated sickle cell phenotypes, and found that Hb-Gower 2 inhibits HbS polymerization (34). Taken together, these studies indicate that reactivation of either fetal or embryonic hemoglobin is beneficial in treating SCA and β-thalassemia.
In conclusion, this study demonstrates that the pharmacological inhibition of BET proteins could significantly alter the composition of hemoglobins, skewing from adult-towards fetal-/embryonic-hemoglobin. Multiple BET inhibitors of different structures were shown to produce similar effects in erythroid cell lines, which suggest that the effects may apply to most, if not all, members in the BET inhibitor family. There are many different BET inhibitors currently under clinical trials for various diseases (35, 36), and the current results showed that patients with SCA or β-thalassemia may benefit from BET inhibition.
The embodiments illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the embodiments claimed. Thus, it should be understood that although the present description has been specifically disclosed by embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of these embodiments as defined by the description and the appended claims. Although some aspects of the present disclosure can be identified herein as particularly advantageous, it is contemplated that the present disclosure is not limited to these particular aspects of the disclosure.
Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
It should it be understood that, in general, where the disclosure, or aspects of the disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/052842 | 9/25/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62907087 | Sep 2019 | US |
